ASCO 2017 - Locally advanced or metastatic solid tumors: GDC-0919+atezolizumab delivers promising phase 1b results

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • Across all dose levels, only 1 DLT and no G 4/5 AEs in this phase 1b trial of the IDO1 inhibitor GDC-0919+the PD-L1 targeting atezolizumab (Tecentriq).

Why this matters

  • Combination generally well tolerated.
  • Demonstrated peripheral IDO1 modulation and preliminary efficacy during dose escalation.
  • Study enrolling more patients in expansion cohorts to assess tumor PD and combination efficacy.

Study design

  • Interventional phase 1b open-label dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GDC-0919+atezolizumab in patients with locally advanced or metastatic solid tumors.
  • Escalating doses of GDC-0919 (50-1000 mg orally twice daily for 21 d) and atezolizumab (1200 mg intravenously every 3 wk) in standard 3+3 design.
  • Funding: Genentech, Inc.

Key results

  • At December 14, 2016, 52 patients had been treated in 6 co...